{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-003332","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.239468+00:00","generated_at":"2026-06-26T00:13:38.370259+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anika Q1 revenue $36.7M (+7% YoY); net loss ($2.9M) vs. income; reaffirms FY22 growth","bullets":["OA Pain Management revenue $22.7M (+18% YoY); Joint Preservation & Restoration $12.1M (-1%).","Net loss ($2.9M), ($0.20) per share vs. net income $2.8M ($0.20 diluted) in prior year.","Adjusted net loss ($1.6M), adjusted gross margin 64% (down YoY) due to supply chain/challenges.","Cash $90.3M; FY2022 revenue expected toward upper end of low-to-mid single digit growth.","Appointed Rob Delp as VP U.S. Sales; he previously led Americas for Zimmer Biomet."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-003332","json":"https://secwatch.observer/filing/0001171843-22-003332.json","markdown":"https://secwatch.observer/filing/0001171843-22-003332.md","text":"https://secwatch.observer/filing/0001171843-22-003332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184322003332/0001171843-22-003332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184322003332/f8k_050522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:13:38.370259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}